 CAMBRIDGE, England BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that interim Phase I results from the Phase III trial of BT8009, a second-generation BTCTM targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA. The 